Federal inspectors found the temperature-sensitive medication improperly stored at Avir at Lubbock during a September complaint investigation. The violations affected multiple residents who depended on the anti-anxiety drug to manage their conditions.
Resident #4, Resident #5, and Resident #6 all had liquid Lorazepam that should have been refrigerated according to pharmacy labels. Instead, nurses kept the medication in rolling carts at room temperature. One resident's bottle carried an illegible label that staff couldn't read.
LVN L explained the consequences to inspectors: "The Lorazepam could evaporate or not have as potency and effectiveness. Then the medication would not work for the resident."
The Assistant Director of Nursing told inspectors she hadn't noticed the liquid Lorazepam in medication carts during her weekly or bi-weekly audits. She acknowledged that nurses and medication aides were responsible for following storage instructions on pharmacy labels.
"There was no reason why the liquid Lorazepam was not in the refrigerator," the ADON stated.
The facility's own policy from January 2018 requires controlled substances needing refrigeration to be stored in locked boxes inside refrigerators. Lorazepam falls under federal controlled substance classifications due to its potential for abuse and dependence.
Staff knew the storage requirements but failed to follow them. LVN L told inspectors she had been trained to place Lorazepam in the refrigerator immediately upon receiving it or identifying it in medication carts. She couldn't explain why the three residents' medications remained at room temperature.
The ADON blamed hospice services for Resident #5's illegible label, saying the medication "was brought to the facility in that condition." But facility policy requires staff to ensure all medication labels are legible and properly adhered to, regardless of their source.
LVN L confirmed that illegible labels should trigger calls to the pharmacy for replacements. The facility's pharmacy consultant told inspectors that unreadable labels required immediate replacement to prevent medication errors.
The pharmacy consultant admitted he was unaware of the storage violations despite conducting regular audits. When asked about potential consequences of improper Lorazepam storage, he said he was "unsure what the potential negative outcome was for the resident."
His uncertainty contrasted sharply with the nursing staff's clear understanding of the risks. The consultant suggested outcomes "may depend on the manufacturer" but couldn't specify how temperature abuse might affect the specific formulations found in violation.
Medication delivery timing complicated the storage issue. LVN L explained that filled dates on pharmacy labels didn't reflect when the facility actually received medications. Deliveries typically arrived at 3:00 AM or 4:00 AM the day after the fill date, creating gaps in the tracking system.
The ADON expected nurses and medication aides to monitor their medication carts and immediately refrigerate temperature-sensitive drugs. She called adherence to pharmacy labels "a nursing standard" that all staff should follow without exception.
But the system failed. Multiple residents went days or weeks with potentially compromised anxiety medication while staff conducted routine audits without detecting the violations. The pharmacy consultant's weekly or bi-weekly reviews missed the storage problems entirely.
Federal regulations require nursing homes to store medications according to manufacturer and pharmacy instructions to maintain their therapeutic effectiveness. Temperature-sensitive psychiatric medications like liquid Lorazepam can lose potency when stored improperly, potentially leaving residents with inadequate symptom control.
The facility's controlled substance policy acknowledges special handling requirements for medications like Lorazepam. Staff must complete accountability records documenting the resident's name, medication details, receipt date, quantity, and receiving person for all controlled substances.
Those accountability measures proved insufficient to catch the storage violations. Three residents continued receiving medication that may have lost effectiveness due to temperature abuse, while supervisors remained unaware of the problem during routine oversight.
LVN L's warning to inspectors captured the human impact: residents depending on Lorazepam for anxiety management could find their medication simply stopped working, leaving them without the psychiatric support their doctors had prescribed.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Avir At Lubbock from 2025-09-05 including all violations, facility responses, and corrective action plans.